Silence Therapeutics (SLN) Total Liabilities (2018 - 2025)
Silence Therapeutics' Total Liabilities history spans 8 years, with the latest figure at $69.1 million for Q4 2025.
- On a quarterly basis, Total Liabilities rose 0.77% to $69.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $69.1 million, a 0.77% increase, with the full-year FY2025 number at $69.1 million, up 0.77% from a year prior.
- Total Liabilities hit $69.1 million in Q4 2025 for Silence Therapeutics, down from $72.7 million in the prior quarter.
- Over the last five years, Total Liabilities for SLN hit a ceiling of $118.2 million in Q4 2021 and a floor of -$22.6 million in Q3 2021.
- Historically, Total Liabilities has averaged $87.3 million across 5 years, with a median of $96.1 million in 2024.
- Biggest five-year swings in Total Liabilities: skyrocketed 569.81% in 2022 and later fell 27.99% in 2024.
- Tracing SLN's Total Liabilities over 5 years: stood at $118.2 million in 2021, then fell by 15.21% to $100.2 million in 2022, then decreased by 4.91% to $95.3 million in 2023, then fell by 27.99% to $68.6 million in 2024, then grew by 0.77% to $69.1 million in 2025.
- Business Quant data shows Total Liabilities for SLN at $69.1 million in Q4 2025, $72.7 million in Q3 2025, and $71.1 million in Q2 2025.